XERIS BIOPHARMA HOLDINGS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Cash and Cash Equivalents, Period Increase (Decrease) of $29.67 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2022-03-11
- XERIS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-12-31 was $7.78M.
- XERIS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-12-31 was -$288.00K.
- XERIS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2021 was $29.67M, a 64.13% increase from fiscal 2020.
- XERIS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2020 was $18.08M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|
| 2021-12-31 | $7.78M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $29.67M 10-K · filed 2022-03-11 | |
| 2021-09-30 | $21.89M 10-Q · filed 2021-11-10 | ||
| 2020-12-31 | -$288.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $18.08M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $18.37M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |